Nimesulide for acute pain and Primary dysmennorhea

Nimesuilde is a pain killer Non-steroidal medicinal drug (NSAIDs) with a complex mode of action which is the best prescribed drug for treatment of acute pain, Primary dysmennorhea and also to treat degenerative joint disease.

 Clinical studies have been carried out in a wide variety of acute inflammatory and painful conditions with the aim of evaluating the analgesic activity of Nimesulide in comparison to placebo.

 In the clinical studies the efficacy of nimesulide was consistently superior to placebo, to that observed for the reference drugs, with a particularly fast onset of the analgesic action.

 The rapid analgesic activity shows reductions for the pain within 15 minutes from drug intake. The drug is available in a variety of forms such as tablets, powder for dissolution in water, suppositories, mouth dissolving tablets and topical gel.

 It’s also available with various brands like Sulide, Nimalox, Nimesil, Nimulid, Nicip, Nimcap, Nise, Sulidene and Zolan.

Nimesulide medicine for Osteoarthritis

Nimesulide drug was launched in Italy for the first time as Aulin and Mesulid in 1985 and is presently available in more than 50 countries worldwide with different trademarks.

Nimesulide is used for the treatment of post-traumatic inflammation, acute musculoskeletal disorders including sprains, strains, tendinitis, tenosynovitis, low back pain, periarthritis (shoulder pain) and osteoarthritis (joint pains), stiffness.

Nimesulide brands such as Sulide, Nimalox, Nimesil, Nimulid, Nicip, Nimcap, Nise, Sulidene and Zolan.

It has superior gastrointestinal safety as compared to other NSAIDs.

It is an analgesic and antipyretic in action. Its multifactorial mode of action gives it a unique and broad action on inflammatory processes.

The maximum duration and dose of a treatment course with Nimesulide medicine is 15 days, 100 mg twice a day, to minimize the risk of hepatotoxicity.

Joint ache influenced by osteoarthritis (OA) which is a gathering of mechanical abnormailities including debasement of joints, and NSAID’s – Nimesulide is most regularly used to treat agony connected with OA.

The primary symptom is agony, creating loss of capacity and regularly stiffness . Osteoarthritis (OA) is brought about by aging joints, damage, and obesity. OA usually influences the hands, feet, spine, and the expansive weight bearing joints, for example, the hips and knees.

Nimesulide proved to be significantly more viable in giving symptomatic relief. Nimesulide speaks to a successful operator for the treatment of joint ache, with specific reference to the quick onset of its pain relieving impact.

Nimesulide has superior gastrointestinal safety as compared to other NSAIDs Its multifactorial mode of action gives it a unique and broad action on inflammatory processes.

It is available in the market in various like tablets (100 mg), granules for oral suspension (100 mg), suppositories (200 mg) and gel (3%).

The Gel needed to be applied is three to four times per day depending on the dimension of the affected size and response. Medicalcare ought to be reviewed after 4 weeks.

Trademarks of NImesulide include of Sulide, Nimalox, Nimesil, Nimulid, Nicip, Nimcap, Nise, Sulidene and Zolan e.t.c.

Nimulid Transgel is indicated for post-traumatic inflammation, acute musculoskeletal disorders including sprains, strains, tendinitis, tenosynovitis, low back pain, periarthritis (shoulder pain) and osteoarthritis (joint pains), stiffness.with multi factorial approach for treating post-traumatic inflammation, acute musculoskeletal disorders including sprains, strains, tendinitis, tenosynovitis, low back pain, periarthritis (shoulder pain) and osteoarthritis (joint pains), stiffness.

It was launched in Italy for the first time as Aulin and Mesulid in 1985 and is presently available in more than 50 countries worldwide in different trademarks

Its multifactorial mode of action gives it a unique and broad action on inflammatory processes.

It is available in the market in various like tablets (100 mg), granules for oral suspension (100 mg), suppositories (200 mg) and gel (3%).

The Gel needed to be applied is three to four times per day depending on the dimension of the affected size and response. Medicalcare ought to be reviewed after 4 weeks.

Trademarks of NImesulide include of Sulide, Nimalox, Nimesil, Nimulid, Nicip, Nimcap, Nise, Sulidene and Zolan e.t.c.

Nimulid Transgel is indicated for post-traumatic inflammation, acute musculoskeletal disorders including sprains, strains, tendinitis, tenosynovitis, low back pain, periarthritis (shoulder pain) and osteoarthritis (joint pains), stiffness.


http://nimesulidedrugforms.blogspot.in/